ASCO 2025: Strand Therapeutics Co-Founder & CEO Jake Becraft discusses the clinical data presentation for the company's IL-12, self-replicating mRNA cancer immunotherapy

He explains why IL-12, and how the self-replicating aspect may be giving this more durability over first generation mRNA cancer immunotherapies. He covers the data, and describes how Strand is seeing the abscopal effect in some patients for this intra-tumoral administered product.